Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy

$200 Per Share Buyout Is 75% Premium

 
• By Mandy Jackson

Merck will reduce its dependence on oncology and expand in immunology, adding a Phase III-ready TL1A inhibitor for IBD that could reach the market a few years ahead of losing exclusivity for Keytruda.

Pain in human intestines, bowel concept
PRA023 will move into Phase III in ulcerative colitis and Crohn's disease in late 2023 or early 2024 • Source: Shutterstock

More from Deals

More from Business